Full Title
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants with Advanced Solid Malignancies Harboring a TP53 Y220C mutationPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Alison Schram’s office at 646-888-4226.
Protocol
26-379
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07752875
ClinicalTrials.gov